Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center Phase II study designed to evaluate the efficacy and
safety of Surufatinib plus anti-PD-1/L1 as maintenance therapy after first-line standard of
care in patients with ES-SCLC.